Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load
复制标题
DOI：
10.1016/j.jacl.2012.02.010
复制
发表时间：
2012-12-01
影响因子：
4.4
通讯作者：
Maffioli, Pamela
中科院分区：
文献类型：
--
作者：
Derosa, Giuseppe;Cicero, Amigo F. G.;Maffioli, Pamela
背景技术背景：口服脂肪负荷（oral fat load，OFL）被认为是最准确的餐后脂蛋白代谢模型之一，已被广泛用于评价餐后脂肪负荷对单个炎症标志物的影响。目的：为了评价n-3 PUFA的作用，主要是二十碳五烯酸（EPA）和二十二碳六烯酸（DHA），每粒胶囊中EPA和DHA的含量分别为400 mg和450 mg，在一项随机、安慰剂对照试验中，在空腹状态和标准化OFL后，对受联合血脂异常影响的患者的金属蛋白酶和炎症生物标志物的影响。在基线和2、4和6个月后，我们评估了体重指数（BMI）、体重、空腹血糖（FPG）、空腹血浆胰岛素（FPI）、稳态模型评估胰岛素抵抗指数（HOMA-IR）、血压、血脂、可溶性细胞间粘附分子-1（sICAM-1）、白细胞介素6（IL-6）、高敏C反应蛋白（hs-CRP）、可溶性血管细胞粘附分子-1（sVCAM-1）、sE-选择素、肿瘤坏死因子-α（TNF-α）和金属蛋白酶2和9（MMP-2和9）。此外，在基线和研究结束时，所有患者均接受了正常血糖高胰岛素钳夹和口服脂肪负荷。（-54 mg/dL）和高密度脂蛋白胆固醇较高与安慰剂相比，n-3 PUFA组（+6 mg/dL）; n-3 PUFA的FPG水平较低（-3 mg/dL），sICAM（-25 ng/mL），IL-6（-0.3 pg/mL），hs-CRP（-0.6 mg/L），sVCAM-1（-89 ng/mL），sE-选择素（-5.8 ng/mL）、TNF-α（-0.3 ng/mL）、MMP-2（-185.1 ng/mL）和MMP-9（-91.5 ng/mL），以及与安慰剂相比更大的M值（+1.21 μ mol/min/kg）。OFL后，有一个减少的Tg，MMPs，和所有炎症参数与n-3 PUFA，但不与placebo.CONCLUSION：补充n-3 PUFA导致较低水平的FPG，血脂，MMPs，和炎症参数，并在一个更好的增加M值相比，安慰剂，无论是在空腹状态和OFL后。(C)2012年国家脂质协会。All rights reserved.
BACKGROUND: The oral fat load (OFL) is considered as one of the most accurate models of postprandial lipoprotein metabolism and it has been widely used to evaluate the postprandial fat load effect on single markers of inflammation.OBJECTIVE: To evaluate the effects of n-3 PUFA, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a content of 400 mg of EPA and 450 mg of DHA in each capsule, on metalloproteinases and inflammatory biomarkers in patients affected by combined dyslipidemia both in a fasting state and after a standardized OFL in a randomized, placebo-controlled trial.METHODS: Placebo or n-3 PUFAs 3 g/day (I g three times a day during the meals) was administered for 6 months. At the baseline, and after 2, 4, and 6 months we evaluated body mass index (BMI), body weight, fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), blood pressure, lipid profile, soluble intercellular adhesion molecule-1 (sICAM-1), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), sE-selectin, tumor necrosis factor-alpha (TNF-alpha), and metalloproteinases 2 and 9 (MMP-2 and 9). Furthermore, at the baseline and at the end of the study, all patients underwent an euglycemic hyperinsulinemic clamp and an oral fat load.RESULTS: Tg levels were lower (-54 mg/dL) and high-density lipoprotein chiolesterol higher (+6 mg/dL) with n-3 PUFAs compared with placebo; n-3 PUFAs gave lower levels of FPG (-3 mg/dL), sICAM (-25 ng/mL), IL-6 (-0.3 pg/mL), hs-CRP (-0.6 mg/L), sVCAM-1 (-89 ng/mL), sE-selectin (-5.8 ng/mL), TNF-alpha (-0.3 ng/mL), MMP-2 (-185.1 ng/mL), and MMP-9 (-91.5 ng/mL), and a greater M value (+1.21 mu mol/min/kg) compared with placebo. After the OFL, there was a decrease of Tg, MMPs, and all inflammatory parameters with n-3 PUFAs, but not with placebo.CONCLUSION: Supplementation with n-3 PUFA resulted in lower levels of FPG, plasma lipids, MMPs, and inflammatory parameters and in a better increase of M value compared to placebo, both in the fasting state and after an OFL. (C) 2012 National Lipid Association. All rights reserved.